Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

SUMOylation coordinates BERosome assembly in active DNA demethylation during cell differentiation.

Steinacher R, Barekati Z, Botev P, Kuśnierczyk A, Slupphaug G, Schär P.

EMBO J. 2019 Jan 3;38(1). pii: e99242. doi: 10.15252/embj.201899242. Epub 2018 Dec 6.

PMID:
30523148
2.

Cosmetic micromanipulation of vitrified-warmed cleavage stage embryos does not improve ART outcomes: An ultrastructural study of fragments.

Safari S, Khalili MA, Barekati Z, Halvaei I, Anvari M, Nottola SA.

Reprod Biol. 2017 Sep;17(3):210-217. doi: 10.1016/j.repbio.2017.05.003. Epub 2017 May 18.

PMID:
28527625
3.

The influence of amifostine administration prior to cyclophosphamide on in vitro maturation of mouse oocytes.

Golkar-Narenji A, Barekati Z, Eimani H, Shabani F, Gourabi H.

J Assist Reprod Genet. 2013 Jul;30(7):939-44. doi: 10.1007/s10815-013-0035-9. Epub 2013 Jul 5.

4.

The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers.

Chen W, Cai F, Zhang B, Barekati Z, Zhong XY.

Tumour Biol. 2013 Feb;34(1):455-62. doi: 10.1007/s13277-012-0570-5. Epub 2012 Dec 14.

PMID:
23238818
5.

Methylation signature of lymph node metastases in breast cancer patients.

Barekati Z, Radpour R, Lu Q, Bitzer J, Zheng H, Toniolo P, Lenner P, Zhong XY.

BMC Cancer. 2012 Jun 13;12:244. doi: 10.1186/1471-2407-12-244.

6.

Superovulation, in vitro fertilization (IVF) and in vitro development (IVD) protocols for inbred BALB/cJ mice in comparison with outbred NMRI mice.

Golkar-Narenji A, Gourabi H, Eimani H, Barekati Z, Akhlaghi A.

Reprod Med Biol. 2012 Apr 7;11(4):185-192. doi: 10.1007/s12522-012-0127-8. eCollection 2012 Oct.

7.

Effects of amifostine in combination with cyclophosphamide on female reproductive system.

Barekati Z, Golkar-Narenji A, Totonchi M, Radpour R, Gourabi H.

Reprod Sci. 2012 May;19(5):539-46. doi: 10.1177/1933719111426599. Epub 2012 Jan 19.

PMID:
22267539
8.

Mutations of mitochondrial DNA as potential biomarkers in breast cancer.

Cai FF, Kohler C, Zhang B, Chen WJ, Barekati Z, Garritsen HS, Lenner P, Toniolo P, Zhang JJ, Zhong XY.

Anticancer Res. 2011 Dec;31(12):4267-71.

PMID:
22199290
9.

Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment.

Radpour R, Barekati Z, Kohler C, Schumacher MM, Grussenmeyer T, Jenoe P, Hartmann N, Moes S, Letzkus M, Bitzer J, Lefkovits I, Staedtler F, Zhong XY.

PLoS One. 2011;6(11):e27355. doi: 10.1371/journal.pone.0027355. Epub 2011 Nov 4.

10.

Cell-free DNA in the circulation as a potential cancer biomarker.

Kohler C, Barekati Z, Radpour R, Zhong XY.

Anticancer Res. 2011 Aug;31(8):2623-8. Review.

PMID:
21778314
11.

Targeted therapy in breast cancer: what's new?

Fang L, Barekati Z, Zhang B, Liu Z, Zhong X.

Swiss Med Wkly. 2011 Jun 27;141:w13231. doi: 10.4414/smw.2011.13231. eCollection 2011. Review.

12.

Assessing the value of CAN-gene mutations using MALDI-TOF MS.

Kohler C, Tavelin B, Fan AX, Radpour R, Barekati Z, Levi F, Zhong XY, Lenner P, Toniolo P.

J Cancer Res Clin Oncol. 2011 Aug;137(8):1239-44. doi: 10.1007/s00432-011-0990-4. Epub 2011 Jun 21.

PMID:
21691751
13.

Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer.

Radpour R, Barekati Z, Kohler C, Lv Q, Bürki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY.

PLoS One. 2011 Jan 24;6(1):e16080. doi: 10.1371/journal.pone.0016080.

14.

Specificity of methylation assays in cancer research: a guideline for designing primers and probes.

Barekati Z, Radpour R, Kohler C, Zhong XY.

Obstet Gynecol Int. 2010;2010. pii: 870865. doi: 10.1155/2010/870865. Epub 2010 Jul 27.

15.

Proteomics and biomarkers for ovarian cancer diagnosis.

Zhang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W, Zhong XY.

Ann Clin Lab Sci. 2010 Summer;40(3):218-25. Review.

PMID:
20689132
16.

Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.

Barekati Z, Radpour R, Kohler C, Zhang B, Toniolo P, Lenner P, Lv Q, Zheng H, Zhong XY.

Hum Mol Genet. 2010 Aug 1;19(15):2936-46. doi: 10.1093/hmg/ddq199. Epub 2010 May 12.

PMID:
20466735
17.

Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer.

Radpour R, Barekati Z, Haghighi MM, Kohler C, Asadollahi R, Torbati PM, Holzgreve W, Zhong XY.

Mod Pathol. 2010 May;23(5):763-72. doi: 10.1038/modpathol.2009.195. Epub 2010 Jan 15.

18.

Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.

Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY.

Mol Cancer. 2009 Nov 17;8:105. doi: 10.1186/1476-4598-8-105.

19.

New trends in molecular biomarker discovery for breast cancer.

Radpour R, Barekati Z, Kohler C, Holzgreve W, Zhong XY.

Genet Test Mol Biomarkers. 2009 Oct;13(5):565-71. doi: 10.1089/gtmb.2009.0060. Review.

PMID:
19814613
20.

Simultaneous isolation of DNA, RNA, and proteins for genetic, epigenetic, transcriptomic, and proteomic analysis.

Radpour R, Sikora M, Grussenmeyer T, Kohler C, Barekati Z, Holzgreve W, Lefkovits I, Zhong XY.

J Proteome Res. 2009 Nov;8(11):5264-74. doi: 10.1021/pr900591w.

PMID:
19780627
21.

Previous maternal chemotherapy by cyclophosphamide (Cp) causes numerical chromosome abnormalities in preimplantation mouse embryos.

Barekati Z, Gourabi H, Valojerdi MR, Yazdi PE.

Reprod Toxicol. 2008 Nov-Dec;26(3-4):278-81. doi: 10.1016/j.reprotox.2008.09.014. Epub 2008 Oct 15.

PMID:
18930809

Supplemental Content

Loading ...
Support Center